AIDAN O’SHEA and his new wife Kristin jetted off to Australia for their honeymoon. The Mayo GAA icon tied the knot at the ...

"Together, AbbVie and Nimble have the potential to help address the significant unmet medical need for people living with autoimmune diseases." "Nimble Therapeutics is committed to transforming ...

The purchase is just the latest in AbbVie acquisitions this year. AbbVie Inc. said Friday it’s buying Nimble Therapeutics of Madison, Wisconsin, for $200 million. North Chicago-based AbbVie ...

If you want to know who really controls AbbVie Inc. (NYSE:ABBV), then you'll have to look at the makeup of its share registry. With 73% stake, institutions possess the maximum shares in the company.

Jan 6 (Reuters) - AbbVie (ABBV.N), opens new tab lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as ...

AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. As part of the acquisition, the North Chicago ...

(RTTNews) - AbbVie Inc. (ABBV), Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along with certain interim funding and milestone payments.

AbbVie has a solid medium-term growth plan and the means to accomplish it. Acquisitions and licensing deals could make for unexpected upsides. Still, its shares aren't priced inexpensively at the ...

Gifting allows recipients to access the article for free. AbbVie is continuing its dealmaking spree with a $200 million acquisition of a biotech firm that spun out of pharmaceutical giant Roche.

AbbVie offers a compelling investment opportunity after a recent price drop, combining dividend income, value, and growth potential driven by a strong drug portfolio and pipeline. Robust growth in ...